BUTENAFINE Drug Patent Profile
✉ Email this page to a colleague
When do Butenafine patents expire, and when can generic versions of Butenafine launch?
Butenafine is a drug marketed by Sun Pharma Canada and is included in one NDA.
The generic ingredient in BUTENAFINE is butenafine hydrochloride. There are two drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the butenafine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Butenafine
A generic version of BUTENAFINE was approved as butenafine hydrochloride by SUN PHARMA CANADA on November 16th, 2017.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for BUTENAFINE?
- What are the global sales for BUTENAFINE?
- What is Average Wholesale Price for BUTENAFINE?
Summary for BUTENAFINE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Prices: | Drug price information for BUTENAFINE |
| DailyMed Link: | BUTENAFINE at DailyMed |
US Patents and Regulatory Information for BUTENAFINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma Canada | BUTENAFINE HYDROCHLORIDE | butenafine hydrochloride | CREAM;TOPICAL | 205181-001 | Nov 16, 2017 | OTC | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |


